CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced favorable safety and efficacy results from a Phase 1b study of IMO-2055, a TLR9 agonist, in combination ...
Switch to Low Sulphur Fuel has Implications for Shore Based Industry Too says ICS. The International Chamber of Shipping (ICS), whose member national shipowners’ associations represent more than 80% ...
A new study has revealed that nearly three-quarters (71 percent) of all new containerships, which emit around a quarter of global ship CO2 emissions, are already in compliance with the post-2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results